Table 1.
Baseline characteristics according to immune recurrence score
| Characteristics | Total (N = 392) | High-risk (N = 31) | Intermediate (N = 265) | Low-risk (N = 96) | P-value |
|---|---|---|---|---|---|
| Age (years) | |||||
| Mean (SD) | 48.5 (9.8) | 48.3 (9.2) | 48.4 (10.2) | 48.8 (8.9) | 0.94 |
| Nuclear grade | |||||
| 1 | 8 (2.0%) | 1 (3.2%) | 4 (1.5%) | 3 (3.1%) | 0.028 |
| 2 | 159 (40.6%) | 9 (29.0%) | 99 (37.4%) | 51 (53.1%) | |
| 3 | 225 (57.4%) | 21 (67.7%) | 162 (61.1%) | 42 (43.8%) | |
| Histology grade | |||||
| I | 32 (8.2%) | 1 (3.2%) | 19 (7.2%) | 12 (12.5%) | 0.003 |
| II | 145 (37.0%) | 8 (25.8%) | 90 (34.0%) | 47 (49.0%) | |
| III | 215 (54.8%) | 22 (71.0%) | 156 (58.9%) | 37 (38.5%) | |
| Lymphovascular invasion | |||||
| Absent | 239 (61.0%) | 14 (45.2%) | 156 (58.9%) | 69 (71.9%) | 0.014 |
| Present | 153 (39.0%) | 17 (54.8%) | 109 (41.1%) | 27 (28.1%) | |
| Stage | |||||
| I | 135 (14.4%) | 8 (25.8%) | 80 (30.2%) | 47 (49.0%) | 0.009 |
| II | 217 (55.4%) | 18 (58.1%) | 159 (60.0%) | 40 (41.7%) | |
| III | 40 (10.2%) | 5 (16.1%) | 26 (9.8%) | 9 (9.4%) | |
| Hormone receptor | |||||
| Negative | 85 (21.7%) | 12 (38.7%) | 60 (22.6%) | 13 (13.5%) | 0.010 |
| Positive | 307 (78.3%) | 19 (61.3%) | 205 (77.4%) | 83 (86.5%) | |
| HER2 | |||||
| Negative | 336 (85.7%) | 24 (77.4%) | 226 (85.3%) | 86 (89.6%) | 0.23 |
| Positive | 56 (14.3%) | 7 (22.6%) | 39 (14.7%) | 10 (10.4%) | |
| Intrinsic subtype | |||||
| Luminal A | 271 (69.1%) | 14 (45.2%) | 181 (68.3%) | 76 (79.2%) | 0.021 |
| Luminal B | 36 (9.2%) | 5 (16.1%) | 24 (9.1%) | 7 (7.3%) | |
| HER2 positive | 32 (8.2%) | 3 (9.7%) | 23 (8.7%) | 6 (6.2%) | |
| Triple-negative | 53 (13.5%) | 9 (29.0%) | 37 (14.0%) | 7 (7.3%) | |
HER2 human epidermal growth factor receptor 2, SD standard deviation